Michael Severino trades in AbbVie perch for CEO role at Flagship’s gene medicines biotech Tessera
After a few years as vice chair and president at what is anticipated to become the world’s largest drugmaker and one of the industry’s leading R&D spenders, AbbVie’s Michael Severino wanted to wear a slightly different hat in a vastly different environment.
The sprawling biotech creations of Flagship Pioneering attracted him, and he was intrigued by the idea of going beyond a temporary fix for diseases and instead dig into genetic medicines in search of the elusive “cure.” Particularly appetizing was Tessera Therapeutics, the biotech at which he took over the helm on Wednesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.